Biota Holdings
Biota was an Australian antiviral drug development company listed on the Australian Stock Exchange (ASX:BTA).
In 1989 Biota discovered the drug Zanamivir, which acts as a neuraminidase inhibitor for the treatment and prevention of influenza. This drug is licensed to GlaxoSmithKline and marketed as Relenza.
In November 2012, Biota Holdings Limited merged with American company Nabi Biopharmaceuticals to form Biota Pharmaceuticals.
The combined company has its headquarters in the U.S. and is now listed on the NASDAQ under the abbreviated code BOTA.
External links
This article is issued from Wikipedia - version of the Sunday, October 18, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.